NewTimeSpace News,According to a disclosure from the Singapore Exchange on March 2, Japan’s Takeda and U.S.-based Protagonist jointly announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Rusfertide and granted it Priority Review status for the treatment of polycythemia vera in adults.
NewTimeSpace: SSY Group Limited (02005.HK) announced a voluntary announcement that the Group has obtained the Drug Production Registration Approval for Doxapram Hydrochloride Injection (5ml:100mg) from the National Medical Products Administration (NMPA) of China.The product is classified as a Category 3 chemical drug and is deemed to have passed the consistency evaluation. It is the first approval among domestic enterprises, mainly indicated for the treatment of respiratory failure.
In 2026, MINIMAX-WP (00100.HK) debuted on the Hong Kong stock market, with its market cap once surpassing HK$300 billion. As of February 27, its market cap was approximately **HK$239.5 billion**, nearly four times its offer price. However, based on the projected 2025 revenue of US$71 million, its **P/S ratio is a high 431x**, far exceeding OpenAI (~64x) and Anthropic (~81x), indicating a significant valuation premium. While revenue for the first three quarters of 2025 was US$53.44 million (up 175%), losses for the same period reached US$512 million, with cumulative losses since inception exceeding RMB 9 billion.
Cambridge Industries Group (06166.HK) conducted a secondary listing in Hong Kong in October 2025, with its shares soaring 33.86% on the first day due to strong Q3 results. However, the stock saw a significant correction entering 2026, with a year-to-date decline of 28.34% as of February 27, leaving the A/H premium at over 70%. Affected by an approximately RMB 81.61 million exchange loss and supply chain fluctuations, the company's Q4 2025 net profit decelerated sharply compared to the RMB 259 million earned in the first three quarters. Currently, the ongoing shortage of upstream optical chips (such as EML) remains the critical bottleneck restricting the release of its AI computing dividends.
NewTimeSpace News: SSY Group Limited (02005.HK) announced in a voluntary disclosure that its metoclopramide and metoclopramide hydrochloride have been approved by the National Medical Products Administration (NMPA) of China for registration as active pharmaceutical ingredients (APIs) for use in marketed finished dosage forms.
Since debuting on the HKEX in January 2026, Knowledge Atlas Tech’s market cap once soared to HK$320 billion, with its share price rising more than 524% from the offer price. Although its new flagship model GLM-5 demonstrates potential on par with top international models, the company’s recent public apology due to restricted service expansion has exposed weaknesses in operations and computing support. The company suffers from "insufficient self-sustenance," with cumulative R&D investment from 2022 to the first half of 2025 reaching RMB 4.4 billion against revenue of only RMB 685 million. Computing costs remain a heavy burden, with approximately 70% of R&D investment used for purchasing computing power.
PHANCY (06682.HK) has issued a clarification announcement regarding market rumors about the impact of AI large models on the software industry. It emphasizes that the company's main computing power business has precisely benefited from the development trend of AI large models. In the first three quarters of 2025, its revenue increased by 36.8% year-on-year and it achieved quarterly profitability for the first time. The board of directors confirms that business operations are normal and that it is not aware of any inside information that should be disclosed but has not been disclosed.
Since its listing in December 2025,Lemo(02539.HK), the "first stock of shared massage chairs," has seen its share price undergo violent fluctuations—first doubling and then being "halved" within two months—recording a single-day drop of nearly 40% in early February 2026. Although the company firmly holds the top spot in the industry with a 42.9% market share, its financial fundamentals are facing severe challenges. The automated massage service market has a limited size, and peers such as Rotai and Ogawa have already scaled back this business; nevertheless,Lemo continues to insist on using 60% of its raised funds for service point expansion.
Zhipu AI raises LLM prices by 30%+ amid strong demand. ChiNext AI ETF Huabao (159363) surges 2%+, with monthly AUM up 1.3B yuan. AI sector investment remains robust as market anticipates AGI advancement.
YouLianCloud leverages Qilin Financial LLM for GEOPlus solutions, restructuring content to EEAT standards. It helps financial institutions shift from voice competition to trust competition, becoming authoritative sources for AI models.
NewTimeSpace News: Nanjing Leads Biolabs Co., Ltd. (09887.HK) announced that the first patient dosing has been completed in the Phase Ib/II clinical trial of its core product Velixin™ (LBL-024) for the treatment of relapsed or metastatic triple-negative breast cancer, marking new progress in the development of this drug for breast cancer indications.
NewTimeSpace News, JIUYUAN GENE announced on February 9 that the Investigational New Drug (IND) application for JY54 Injection, a self-developed Class 1 chemical innovative drug, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. The drug is focused on weight management for obese or overweight populations and has demonstrated excellent preclinical data.
NewTimeSpace News: Peijia Medical Limited (09996.HK) announced on February 9, 2026 that the company has recently officially submitted the EU MDR CE mark registration application for its self-developed GeminiOne® Transcatheter Edge-to-Edge Repair System for the treatment of mitral regurgitation, marking progress in the product's global strategic layout. The registration application for the product in China has also been accepted, and it has obtained approval from the US FDA to initiate early clinical studies.
NewTimeSpace News, SKB BIO-B announced on February 6 that its core product TROP2 ADC sacituzumab govitecan (sac-TMT) has obtained approval from the National Medical Products Administration (NMPA) for the launch of its fourth indication, targeting the treatment of a specific type of HR+/HER2- breast cancer.
On February 4, 2026, affected by the sell-off in software stocks triggered by overseas AI automation tools, global e-commerce SaaS leader JST (06687.HK) recorded its largest single-day decline since listing. As of the close on February 5, the stock JST has cumulatively fallen 28.10% since its October 2025 IPO. The market is questioning whether AI will shrink pricing margins for software and destabilize the traditional subscription model, leaving the software industry facing a severe "replacement crisis."
NewTimeSpace News,HENLIUS announced in an announcement on February 5 that it has entered into a license agreement with Eisai, a listed Japanese pharmaceutical company, authorizing Eisai to develop, manufacture and commercialize Hansoh® (Serplulimab Injection) for the treatment of oncology indications in Japan.
